TTToshihiro Tamura

Toshihiro Tamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Toshihiro Tamura has a total of 569 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute Coronary Syndrome in Kawasaki Disease From Infancy to Adulthood

    by Pei-Ni Jone, Jane W. Newburger, Jane C. Burns, Matthew I. Tomey, André Jakob, Yasutsugu Shiono, Satsuki Fukushima, Yoshihide Mitani, Ming-Tai Lin, Alain Fraisse, et al.

    Acute coronary syndrome (ACS) remains underrecognized in patients with Kawasaki disease (KD). The population at risk for KD-associated ACS is increasing, yet current ACS guidelines are largely derived from atherosclerotic disease and do not adequately address the distinctive mechanisms, anatomy, and thrombosis risk associated with KD. Because the pathophysiology and management of KD-associated ACS differ in fundamental ways from those of atherosclerotic coronary artery disease, its management requires a coordinated team response, with collaboration between pediatric and adult cardiologists. Recent advances in coronary imaging, interventional techniques, and antithrombotic therapies provide an opportunity to establish a more disease-specific approach. This review synthesizes current evidence on the epidemiology and pathophysiology of coronary artery aneurysms, interventional coronary imaging, acute management, revascularization strategies, antithrombotic therapy, and post-ACS surveillance in patients with KD to guide clinical decision-making and treatment for patients with KD presenting with ACS.

  • Open Access

    Management and Outcomes of Cardiac Sarcoidosis: Insights From the Nationwide MYSTICS Registry

    by Chisato Izumi, Yusuke Yoshikawa, Issei Komuro, Ken-Ichi Hirata, Koh Ono, Yasushi Sakata, Fumio Terasaki, Takafumi Suda, Hidekazu Tanaka, Toshihiro Tamura, et al.

    BACKGROUND: Cardiac sarcoidosis (CS) may lead to serious outcomes, but large-scale data are lacking because of its rarity, diagnostic uncertainty, and heterogeneous clinical presentations. Actual management and outcomes, including recurrence, are not well understood. This study aimed to clarify the actual management and outcomes of CS from a nationwide large-scale registry. METHODS: This multicenter retrospective registry enrolled 2366 consecutive patients with CS. Of these, 1852 patients newly diagnosed between 2012 and 2021 were analyzed. Patients were stratified into 4 groups: definite CS, probable CS, presumed systemic sarcoidosis, and presumed isolated CS based on diagnostic criteria. The primary end point was a composite of all-cause death, heart failure hospitalization, or fatal ventricular arrhythmic event. The secondary end point was recurrence of CS. RESULTS: Cardiac imaging performance rates were high (cardiac magnetic resonance: 64%, 18 F-fluorodeoxyglucose positron emission tomography: 82%), and 974 (53%) patients were diagnosed clinically without histological evidence. During a median 5.1-year follow-up, the primary outcome occurred in 519 (28%, 6.4/100 patient-years) patients, and the 4 groups exhibited different clinical presentations and prognoses; definite CS and presumed isolated CS groups showed a high incidence of the primary end point, fatal ventricular arrhythmic event, hospitalization for heart failure, and cardiovascular death. Most patients (89%) received immunosuppressive therapy, but 291 (18%, 4.1/100 patient-years) patients developed recurrence during steroid tapering, with a 5-year recurrence rate of 17.0%. Recurrence was associated with subsequent primary end point (hazard ratio, 1.38 [95% CI, 1.00–1.89]; P =0.048). CONCLUSIONS: This large-scale multicenter registry showed that clinical presentation and prognosis differ depending on the presence or absence of extracardiac lesions and histological evidence; therefore, it is necessary to recognize the characteristics of each phenotype in managing CS.

  • Sex Differences in Characteristics and Outcomes Among Patients With Hypertrophic Cardiomyopathy: Insights From the REVEAL‐HCM Study

    by Masayuki Nakamura, Haruhiko Abe, Yasunori Ueda, Hiroaki Kitaoka, Yasushi Sakata, Kaoru Dohi, Yukichi Tokita, Takao Kato, Shouji Matsushima, Masashi Amano, et al.

    Background: Female sex has been associated with poor prognosis in hypertrophic cardiomyopathy (HCM), but the factors contributing to this disparity remain insufficiently defined. We aimed to clarify sex differences in clinical characteristics and factors associated with cardiovascular death in Japan. Methods: This multicenter, retrospective observational study of HCM was conducted between January 1, 2006, and December 31, 2018 (REVEAL‐HCM study [Multicenter Registry to Evaluate Risk Factors for Disease Progression, Sudden Cardiac Death and Adverse Clinical Outcomes in Japanese Patients With Hypertrophic Cardiomyopathy]; UMIN000046932). Patients aged ≥16 years with HCM were enrolled. Baseline characteristics and clinical outcomes including cardiovascular death were assessed. Univariable and multivariable Cox proportional hazards models were used to identify factors associated with cardiovascular death. Results: Of 3247 patients (median age, 67 years; 43% women), women were older and more symptomatic at presentation (52% New York Heart Association class II–IV versus 35% in men). Cardiovascular death was more common in women (hazard ratio [HR], 1.37 [95% CI, 1.02–1.82]; P =0.03). In multivariable analysis, older age (per 1‐year increase; HR, 1.04 [95% CI, 1.02–1.06]), advanced New York Heart Association class (HR, 1.99 [95% CI, 1.40–2.82]), history of atrial fibrillation (HR, 1.55 [95% CI, 1.10–2.18]), greater maximal wall thickness indexed to body surface area (per 1‐mm/m 2 increase; HR, 1.12 [95% CI, 1.06–1.20]), and apical HCM (HR, 0.53 [95% CI, 0.32–0.88]) were independently associated with cardiovascular death, attenuating the HR for female sex. Conclusions: Sex differences in clinical characteristics and outcomes were observed. The excess cardiovascular death in women with HCM was largely explained by older age, more advanced symptoms, greater indexed wall thickness, and sex‐specific differences in both the prevalence and prognostic impact of apical HCM.


  • Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort

    by Hirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kazuaki Imada, Satoru Suwa, Tsuyoshi Isawa, et al.

    BACKGROUND: Clopidogrel may have ischemic benefit over aspirin as long-term monotherapy in patients receiving percutaneous coronary intervention. METHODS: Both the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy-2) and STOPDAPT-2 ACS (Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study for the Patients With Acute Coronary Syndrome) were multicenter, open-label, adjudicator-blinded, randomized clinical trials in Japan, with the same protocol except that the STOPDAPT-2 ACS enrolled patients with acute coronary syndrome, exclusively. The patients after percutaneous coronary intervention with cobalt-chromium everolimus-eluting stents were randomized into 1-month dual antiplatelet therapy followed by clopidogrel monotherapy (clopidogrel group) or 12-month dual antiplatelet therapy followed by aspirin monotherapy (aspirin group). Follow-up duration was 5 years. The clinical effect between clopidogrel and aspirin monotherapy was compared by the 1-year landmark analysis in the STOPDAPT-2 ACS and STOPDAPT-2 total cohort, a pooled cohort of the 2 trials. The primary end point was the composite of cardiovascular end point (cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis) and bleeding end point (Thrombolysis in Myocardial Infarction major/minor). The major secondary end points were each of the cardiovascular composite end point and the bleeding end point. RESULTS: Of 2986 patients (clopidogrel group: 1492, aspirin group: 1494) in the 5-year analysis of the STOPDAPT-2 ACS, 2875 (96.3%) completed follow-up. By the 1-year landmark analysis, clopidogrel group was superior to aspirin group for both the primary end point (6.18% and 8.27%; hazard ratio, 0.75 [95% CI, 0.57–0.997]; P =0.048) and the major secondary cardiovascular end point (4.73% and 6.77%; hazard ratio, 0.70 [95% CI, 0.51–0.96]; P =0.03). In the STOPDAPT-2 total cohort, including 5991 patients, the superiority of clopidogrel over aspirin for the cardiovascular end point was highly significant (hazard ratio, 0.74 [95% CI, 0.60–0.91]; P =0.004), although the superiority on the primary end point was insignificant (hazard ratio, 0.86 [95% CI, 0.72–1.03]; P =0.11). There was no between-groups difference in the major secondary bleeding end point, both in the STOPDAPT-2 ACS and STOPDAPT-2 total cohort. CONCLUSIONS: Clopidogrel monotherapy was superior to aspirin monotherapy for cardiovascular outcomes beyond 1 year after percutaneous coronary intervention, without increased bleeding risk. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02619760 and NCT03462498.


  • Long-Term Clinical Outcomes With Defect-Free Care Adherent to the Performance Measures in Patients with STEMI Undergoing PCI in Japan

    by Hiroki Shiomi, Takeshi Morimoto, Manabu Ogita, Tomohisa Tada, Yuki Kuroda, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Natsuhiko Ehara, Ryoji Taniguchi, et al.

    BACKGROUND: Adherence to the clinical performance measures has been advocated in ST-segment–elevation acute myocardial infarction (STEMI) care worldwide. We aimed to examine the association between adherence to these performance measures and long-term clinical outcomes in patients with STEMI undergoing percutaneous coronary intervention. METHODS: The CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) AMI Registry Wave-2 was a multicenter registry conducted at 22 centers in Japan between 2011 and 2013, enrolling consecutive acute myocardial infarction patients who underwent coronary revascularization. The exposures were adherence to 9 guideline-based performance measures for STEMI care, including early reperfusion, evidence-based medical therapy, and cardiac rehabilitation. The primary outcome measure was all-cause death. The secondary outcome measures included cardiovascular death, myocardial infarction, stroke, heart failure hospitalization, major bleeding, and repeat coronary revascularization. Outcomes were assessed over a median follow-up of 6.0 years (interquartile range, 5.1–6.8). Adjusted hazard ratios with 95% CIs were estimated using Cox proportional hazards models, adjusting for baseline characteristics. RESULTS: Among 2892 patients with STEMI who underwent percutaneous coronary intervention within 24 hours after symptom onset and survived to discharge (mean age, 67±13 years; 23% women), patients were categorized according to the number of fulfilled performance measures (PMs=9: N=551, PMs=8: N=985, PMs=7: N=794, and PMs≤6: N=562). As the adherence categories decreased from PMs=9 to PMs≤6, the cumulative 5-year incidence of all-cause death increased from 8.9% to 23.6%. Relative to PMs=9, the adjusted hazard ratio (95% CI) for all-cause death was 1.14 (0.83–1.57) in PMs=8, 1.36 (0.99–1.87) in PMs=7, and 1.96 (1.43–2.69) in PMs≤6, respectively. These inverse associations were observed between adherence to performance measures and most clinical outcomes except for repeat coronary revascularization (adjusted hazard ratio, 1.00 [95% CI, 0.82–1.21] in PMs=8, 0.89 [0.72–1.09] in PMs=7, and 0.91 [0.72–1.15] in PMs≤6, respectively). CONCLUSIONS: Defect-free care adherent to the performance measures was associated with improved long-term clinical outcomes, including lower mortality, among patients with STEMI undergoing percutaneous coronary intervention, whereas no association was observed for repeat coronary revascularization.

  • Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study

    by Yuki Obayashi, Takao Kato, Hiroki Shiomi, Kiyomasa Nakatsuka, Hiroaki Kitaoka, Yasushi Sakata, Kaoru Dohi, Yukichi Tokita, Shouji Matsushima, Masashi Amano, et al.

    BACKGROUND: Mitral regurgitation (MR) is a frequent comorbidity in patients with hypertrophic cardiomyopathy (HCM), which includes distinct subtypes with various characteristics. However, data on the long-term prognostic impact of MR and its progression or regression over time remain limited, particularly across individual HCM subtypes. METHODS: Patients with HCM were retrospectively included from a Japanese multicenter registry and compared by MR severity (moderate or greater versus mild or less) within each subtype: hypertrophic obstructive cardiomyopathy (HOCM), end-stage HCM (ES-HCM), and other HCM (including nonobstructive, midventricular obstruction, and apical HCM). RESULTS: Among 3602 patients (HOCM: n=837; ES-HCM: n=275; other HCM: n=2490), the prevalence of moderate or greater MR was highest in HOCM (36.3%), followed by ES-HCM (21.5%) and other HCM (8.5%). During a median follow-up of 5.3 (interquartile range, 2.1–9.3) years, the cumulative 5-year incidence of all-cause death or heart failure hospitalization was not significantly different between the moderate or greater MR and mild or less MR groups in HOCM (14.6% versus 12.4%; P =0.35) or ES-HCM (60.7% versus 54.7%; P =0.84). After adjustment for clinical covariates, no significant association was observed in either subtype (HOCM: hazard ratio, 1.13 [95% CI, 0.79–1.60], P =0.51; ES-HCM: hazard ratio, 0.84 [95% CI, 0.55–1.28], P =0.42). In contrast, in other HCM, moderate or greater MR was significantly associated with the higher 5-year cumulative incidence of all-cause death or heart failure hospitalization (34.2% versus 13.9%, P P =0.01; P interaction =0.02). MR severity improved over time in HOCM, showed no clear change in ES-HCM, and worsened in other HCM ( P P interaction <0.001). CONCLUSIONS: In patients with HCM, moderate or greater MR was not associated with worse outcomes in HOCM or ES-HCM, but had significant prognostic implications in other HCM subtypes, suggesting the need for HCM subtype-specific MR management.


  • Perspectives of multidisciplinary healthcare professionals on regional medical cooperation (2nd report): The role of acute care hospitals and challenges in regional medical cooperation toward 2040

    by Noriko Kawai, Miyuki Onoi, Masaya Ohana, Yasuaki Hayashino, Michikazu Takahashi, Natsuko Fukuda, Hideki Tsujita, Masato Hirase, Toshihiro Tamura, Yoshihiro Himura, et al.

  • Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation

    by Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, et al.

    BACKGROUND: There were no previous studies comparing aspirin with clopidogrel on top of oral anticoagulation (OAC) within 1 year after percutaneous coronary intervention when dual therapy with OAC and clopidogrel was recommended. METHODS: We conducted a subgroup analysis stratified by OAC in the 1-year follow-up of the STOPDAPT-3 trial (Short and Optimal Duration of Dual Antiplatelet Therapy-3), which randomly compared 1-month dual antiplatelet therapy followed by aspirin monotherapy (aspirin group) with 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group). This subgroup analysis compared aspirin with clopidogrel in patients with or without OAC by the 30-day landmark analysis. The coprimary end points were the cardiovascular (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke), and bleeding end points (Bleeding Academic Research Consortium 3 or 5). RESULTS: In the 30-day landmark analysis (N=5809), there were 788 patients (13.6%) with OAC at discharge. Regardless of OAC, the incidence rates beyond 30 days up to 1 year were similar between the aspirin and clopidogrel groups for cardiovascular end point (OAC: 3.7% versus 3.9%, hazard ratio, 0.92 [95% CI, 0.44–1.93]; no OAC: 3.7% versus 3.6%; hazard ratio, 1.03 [95% CI, 0.77–1.38]; P interaction=0.78) and for bleeding end point (OAC: 3.5% versus 4.2%, hazard ratio, 0.82 [95% CI, 0.39–1.73]; no OAC 1.5% versus 1.4%, hazard ratio, 1.07 [95% CI, 0.66–1.72]; P interaction=0.57). CONCLUSIONS: Aspirin compared with clopidogrel was associated with similar cardiovascular and bleeding outcomes beyond 30 days and up to 1 year after percutaneous coronary intervention regardless of OAC at discharge. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04609111.


  • Open Access

    Echocardiographic measurement of inferior vena cava diameter for estimating central venous pressure in adult Fontan patients

    by Makoto Miyake, Hiraku Doi, Yu Noguchi, Kyokun Uehara, Toshihiro Tamura

    Aims: In adult Fontan patients, a higher central venous pressure (CVP) is associated with worse clinical outcomes. Assessing CVP is helpful to guide therapeutic strategies; however, it remains unclear whether CVP can be accurately estimated from the inferior vena cava (IVC) diameter by echocardiography. Methods and results: This single-centre, retrospective study enrolled 21 adult Fontan patients (median age: 21.5 years, 52% male) who had a transthoracic echocardiogram performed after admission for a scheduled cardiac catheterization. The relationship between CVP estimated by echocardiography and CVP measured by catheterization was investigated. According to echocardiographic guidelines, CVP was estimated to be 3, 8, or 15 mmHg on the basis of the IVC diameter and its respiratory collapse. To evaluate the agreement between estimated and measured CVP grades, measured CVP was also classified into three grades. The mean IVC diameter and measured CVP were 1.41 ± 0.27 cm and 11.9 ± 2.8 mmHg, respectively. Both the IVC diameter and the estimated CVP grade were correlated with measured CVP (r = 0.526, P = 0.014 and rho = 0.573, P = 0.007, respectively). However, the estimated CVP grade was concordant with the measured CVP grade in only two patients. In the remaining 19 patients (90%), the estimated CVP grade was lower than the measured CVP grade. Only slight agreement was observed between these two gradings of CVP [weighted kappa coefficient: 0.13, 95% confidence interval (CI): 0.00–0.25]. Conclusion: In adult Fontan patients, the echocardiographic classification of CVP grading using the IVC diameter may underestimate CVP, suggesting that this echocardiographic method cannot replace invasive methods in accurately assessing CVP.


  • Open Access

    A case of typical atrioventricular nodal reentrant tachycardia successfully induced by ventricular-triggered atrial pacing

    by Masaya Akiyama, Shintaro Yamagami, Yuta Nakano, Sosuke Sugimura, Masanori Murayama, Kazushige Shimizu, Sadanori Shimizu, Hiroaki Shima, Tsukasa Motoyoshi, Toyoki Okuda, et al.

    房室結節二重伝導路におけるAH間隔のjump up現象(jump up)は通常型房室結節回帰性頻拍(atrioventricular nodal reentrant tachycardia; AVNRT)において,回旋開始時の機序として重要である.一方で明らかなjump upを認めず誘発及び治療が困難な症例もある.新たなプログラム刺激法として,心室波をtriggerし,心房のpacingを行う心室同期心房pacing(ventricular-triggered atrial pacing; VTAP法)が報告された.VTAP法では一拍前の房室伝導を加味したA-A間隔の緩やかな短縮による誘発性の向上や1:1の遅伝導路(slow pathway)の伝導性の評価が可能とされた.今回VTAP法が治療に有用であった症例を経験したので報告する.症例は70歳男性,突然発症の動悸のため当院へ搬送,発作性上室性頻拍(paroxysmal supraventricular tachycardia; PSVT)と診断されアブレーションの目的で入院となった.電気生理学的検査を施行,室房伝導を認め,心房最早期興奮部位はHis束電位記録部位,減衰伝導特性も認めた.心房期外刺激でjump upを伴ってPSVTが誘発され,右室心尖部(RVA)からのentrainment pacingでpost pacing intervalはTCL + 140 ms, VAV patternで頻拍は持続した.頻拍中のatrial differential pacingでVA linkingを認め,RVAからの単発刺激ではreset現象を認めなかった.以上の結果から通常型AVNRTであると診断され,cryoablationの方針となった.電位指標に解剖学的slow pathway領域を−40℃のcryomapping modeにて冷却し,頻拍周期の延長を認めたものの温度が安定せず,冷却は中断された.その後頻拍停止し,心房期外刺激ではjump upせず,頻拍の誘発は困難となった.そこでVTAP法を行ったところA-A間隔の減少後に100 ms以上のjump upを再現性を持って認め,頻拍の誘発も可能であった.再度slow pathway領域へアプローチし,cryomapping modeでjump up消失をVTAP法にて確認,−80℃のcryoablation modeでの冷却を行った.周辺への追加冷却も行い薬剤負荷・プログラム刺激で頻拍の誘発を認めず,VTAP法でもslow pathway伝導の消失が維持されており終了した.VTAP法によってのみslow pathway伝導の同定や頻拍の誘発が可能となった症例を経験した.